Holen Sie sich die Stockscreener-App
9.70
7.27%
-0.76
Handel nachbörslich:
10.00
0.30
+3.09%
Schlusskurs vom Vortag:
$10.46
Offen:
$10.43
24-Stunden-Volumen:
236.82K
Relative Volume:
0.05
Marktkapitalisierung:
$86.25M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.82M
KGV:
-8.4605
EPS:
-1.1465
Netto-Cashflow:
$-8.00M
1W Leistung:
-18.83%
1M Leistung:
+33.61%
6M Leistung:
+467.25%
1J Leistung:
+394.90%
1-Tages-Spanne:
$9.65
$11.38
1-Wochen-Bereich:
$9.65
$12.72
52-Wochen-Spanne:
$0.72
$20.32
Edesa Biotech Inc Stock (EDSA) Company Profile
Firmenname
Edesa Biotech Inc
Sektor
Branche
Telefon
(905) 475-1234
Adresse
100 SPY COURT, MARKHAM, ON
Compare EDSA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
9.70 | 93.01M | 0 | -7.82M | -8.00M | -1.1465 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Edesa Biotech Inc Aktie (EDSA) Neueste Nachrichten
Edesa Biotech, Inc. (EDSA) Presents at Dermatology Drug Development Summit 2026Slideshow - Seeking Alpha
Edesa Biotech, Inc.Common Shares (NQ: EDSA - FinancialContent
EDSA: Preparing for Mid-2026 Start to Phase 2 Vitiligo Trial - Zacks Small Cap Research
Edesa Biotech Inc. (EDSA) Q1 2026 Earnings: Wider Than Expected Loss as Clinical Pipeline ProgressesExpert Momentum Signals - Newser
EDSA Should I Buy - Intellectia AI
EDSA Stock Price, Quote & Chart | EDESA BIOTECH INC (NASDAQ:EDSA) - ChartMill
Key facts: Edesa Biotech Q2 Loss $4.2M; to Present AKI Data - TradingView
Edesa Biotech, Inc. (EDSA) Presents at Respiratory Innovation Summit 2026Slideshow (NASDAQ:EDSA) 2026-05-19 - Seeking Alpha
What's going on in today's session - ChartMill
Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference - GlobeNewswire
Stonepine entities report 30,000-share stake in Edesa Biotech (EDSA) - Stock Titan
EDESA (EDSA) Schedule 13G/A amendment: Nantahala and principals report 0 shares - Stock Titan
Point72, Steven Cohen report 2 Edesa Biotech shares (NASDAQ: EDSA) - Stock Titan
Rubric Capital and Rosen Hold 7.74% of EDSA (NASDAQ: EDSA) - Stock Titan
Edesa Biotech to issue 90% of CEO’s salary as restricted share units - Investing.com UK
Edesa Biotech Boosts CEO Equity-Based Compensation Structure - TipRanks
Edesa Biotech 8-K Filing: Board Approves CEO Compensatory Arrangements – Key Details from May 2026 SEC Report - Minichart
Edesa Biotech | 8-K: Current report - Moomoo
Edesa Biotech (NASDAQ: EDSA) CEO opts to receive 90% of salary in RSUs - Stock Titan
Sirenia (EDSA) discloses 600,000-share, 7.2% stake in Edesa Biotech - Stock Titan
Edesa Biotech Advances on Two Fronts, Tackling Vitiligo and ARDS - BriefGlance
Edesa Biotech 2Q Loss/Shr 49c >EDSA - Moomoo
Edesa Biotech Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Edesa Biotech, Inc. 2Q 2026: Revenue ($4.23M), Net income ($4.22M), EPS ($0.49) — 10-Q Summary - TradingView
Edesa Biotech (NASDAQ: EDSA) widens losses and warns of going concern risk - Stock Titan
Edesa Biotech reports Q2 FY2026 net loss $4.2M; cash $10.0M, working capital $8.2M - TradingView
Edesa Biotech Q2 net loss widens as R&D spending rises - TradingView
Edesa Biotech (NASDAQ: EDSA) ramps R&D as Q2 2026 loss reaches $4.2M - Stock Titan
Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results - GlobeNewswire
Drug data show ARDS treatment benefits as vitiligo trial nears - Stock Titan
What you need to know before buying Edesa (EDSA) (Underperforming) 2026-05-11Virgin POC - Newser
Number of shareholders of Edesa Biotech, Inc. – NASDAQ:EDSA - TradingView
Edesa Biotech Company Profile & Introduction - Moomoo
Edesa Biotech's Market Cap Up US$44m Following Year Of Insider Stock Buying - simplywall.st
Edesa Biotech (EDSA) CEO awarded 1,159 RSUs and reports updated share holdings - Stock Titan
Edesa Biotech, Inc. Common Shares (EDSA) Stock Price Today & Analysis - Gotrade
EDSA (Edesa) posts 39 percent positive EPS surprise for Q1 2026, shares jump 11.5 percent today.Quick Ratio - newser.com
Short Interest in Edesa Biotech, Inc. (NASDAQ:EDSA) Decreases By 32.5% - MarketBeat
EDSA - Finviz
Edesa Biotech reports FQ1 net loss of $2.2 million - MSN
EDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-Cap Biotech? - Stocktwits
Edesa Biotech Stock Soars 54%: What’s Driving the ARDS Drug Rally Now - TechStock²
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Edesa (EDSA) Stock: Should You Take Exposure (Investors Pile In) 2026-04-27Community Pattern Alerts - Newser
Edesa Biotech Reaches US$68m Market Cap Benefiting Insider Stock Buying - Yahoo Finance
EDSA Edesa Biotech Inc. Common Shares posts narrower Q1 2026 loss than consensus forecasts, shares gain on upbeat investor sentiment.Cost Structure - Cổng thông tin điện tử tỉnh Tây Ninh
Edesa Biotech Schedules Phase 2 Vitiligo Study for Mid-2026 - HarianBasis.co
Edesa (EDSA) Stock Insider Buying (Breakout Watch) 2026-04-20Most Discussed Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Edesa Biotech (EDSA) Reaffirms 2026 Clinical Study Timeline for Vitiligo Treatment - Yahoo Finance
Is Edesa (EDSA) Stock a Growth Stock? (Recovers) 2026-04-16MA Crossover - Cổng thông tin điện tử tỉnh Lào Cai
Finanzdaten der Edesa Biotech Inc-Aktie (EDSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Edesa Biotech Inc-Aktie (EDSA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nijhawan Pardeep | Chief Executive Officer |
Mar 10 '26 |
Buy |
6.60 |
1,000 |
6,599 |
628,813 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 05 '26 |
Buy |
3.90 |
10,000 |
39,000 |
402,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 04 '26 |
Buy |
4.26 |
10,000 |
42,560 |
392,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 03 '26 |
Buy |
3.63 |
10,000 |
36,300 |
382,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 02 '26 |
Buy |
2.00 |
2,000 |
4,000 |
627,813 |
| Nijhawan Pardeep | Chief Executive Officer |
Mar 02 '26 |
Buy |
2.28 |
1,000 |
2,280 |
372,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Feb 27 '26 |
Buy |
2.22 |
30,000 |
66,696 |
371,702 |
| Nijhawan Pardeep | Chief Executive Officer |
Feb 26 '26 |
Buy |
1.58 |
20,571 |
32,480 |
615,797 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):